ESR1 and neoplasm: Another recent study focusing on HR low (ER and PgR) showed that patients with HER2 − HR-low tumours had significantly worse survival than HER2 − HR-positive tumours; by contrast in HER2 + tumours no difference was observed between the 3 HR groups [22].